The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1115-1121

  Clozel, Martine ^a   Hess, Patrick ^a   Qiu, Changbin ^b   Ding, Shuang Shuang ^b   Rey, Markus ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 058362; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID; NEUROPEPTIDE RECEPTOR; PALOSURAN; RECEPTOR BLOCKING AGENT; STREPTOZOCIN; UNCLASSIFIED DRUG; UROTENSIN II RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DESTRUCTION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG SELECTIVITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SYNTHESIS; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; LIPID BLOOD LEVEL; LONG TERM CARE; LONG TERM EXPOSURE; MALE; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEINURIA; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; STREPTOZOCIN DIABETES; SURVIVAL RATE;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; KIDNEY; MALE; PANCREAS; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; STREPTOZOCIN; UREA;

EID: 33644754588     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.094821     Document Type: Article

References (40)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (Lond) 401:282-286.
2. Anderson S, Rennke HG, and Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Investig 77:1993-2000.
3. Churchill P, Churchill M, Bidani A, and Dunbar J Jr (1993) Streptozotocin-induced renal hemodynamic changes in isogenic Lewis rats: a kidney transplant study. Am J Physiol 264:F100-F105.
4. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, et al. (2004) Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311:204-212.
5. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, and Vaudry H (1998) Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95:15803-15808.
6. Davidson WD and Sackner MA (1963) Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62:351-356.
7. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, and Vanhoutte PM (2000) Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974.
8. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, and Clozel M (2003) Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 42:48-54.
9. Douglas SA and Ohlstein EH (2000) Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10:229-237.
10. Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME, Kim Y, and Feiner HD (1990) Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259:F598-F604.
11. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, and Levin RI (1996) Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. Hypertension 27:245-250.
12. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, et al. (2002) Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136:9-22.
13. Fuhr J, Kaczmarczyk J, and Kruttgen CD (1955) A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics. Klin Wochenschr 33:729-730.
14. Gendron G, Simard B, Gobeil F Jr, Sirois P, D'Orleans-Juste P, and Regoli D (2004) Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats. Can J Physiol Pharmacol 82:16-21.
15. King AJ, Brenner BM, and Anderson S (1989) Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 256:F1051-F1058.
16. Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM, and Gilbert RE (2004) Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44:826-831.
17. Lee CS, Mauer SM, Brown DM, Sutherland DE, Michael AF, and Najarian JS (1974) Renal transplantation in diabetes mellitus in rats. J Exp Med 139:793-800.
18. Maguire JJ, Kuc RE, and Davenport AP (2000) Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131:441-446.
19. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, and Davenport AP (2004) Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25:1767-1774.
20. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, and Hirata Y (2001) Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19:2185-2190.
21. Nathan DM, Singer DE, Hurxthal K, and Goodson JD (1984) The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 310:341-346.
22. O'Donnell MP, Kasiske BL, Daniels FX, and Keane WF (1986) Effects of nephron loss on glomerular hemodynamics and morphology in diabetic rats. Diabetes 35:1011-1015.
23. Onan D, Pipolo L, Yang E, Hannan RD, and Thomas WG (2004) Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18:2344-2354.
24. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, and Bern HA (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77:5021-5024.
25. Qiu C, Engels K, and Baylis C (1994) Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol 266:R1470-R1476.
26. Qiu C, Engels K, and Baylis C (1995) Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol 6:1476-1481.
27. Reichard P, Nilsson BY, and Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309.
28. Riddle M (2000) Combining sulfonylureas and other oral agents. Am J Med 108 (Suppl 6a):15S-22S.
29. Shenouda A, Douglas SA, Ohlstein EH, and Giaid A (2002) Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 50:885-889.
30. Sheridan MA and Bern HA (1986) Both somatostatin and the caudal neuropeptide, urotensin II, stimulate lipid mobilization from coho salmon liver incubated in vitro. Regul Pept 14:333-344.
31. Sheridan MA, Plisetskaya EM, Bern HA, and Gorbman A (1987) Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66:405-414.
32. Silvestre RA, Rodriguez-Gallardo J, Egido EM, and Marco J (2001) Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33:379-381.
33. Smith HW, Finkelstein N, Aliminosa L, Crawford B, and Graber M (1945) The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Investig 24:388-404.
34. Steffes MW, Brown DM, and Mauer SM (1978) Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes 27:35-41.
35. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, and Murakami O (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104:1-5.
36. Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, and Imai Y (2004) Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25:1809-1814.
37. Watanabe T, Pakala R, Katagiri T, and Benedict CR (2001) Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104:16-18.
38. Watson AM, Lambert GW, Smith KJ, and May CN (2003) Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42:373-379.
39. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, and Oka Y (2003) Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46:972-976.
40. Zbinden G (1976) The role of pathology in toxicity testing, in Progress in Toxicology: Special Topics, pp 8-18, Springer-Verlag New York Inc., New York.